STOCK TITAN

Entrada Therapeutics, Inc. (TRDA) Revenue by Year

TRDA

Entrada Therapeutics, Inc. generated $25.4M in revenue in fiscal year 2025. This represents a decrease of 87.9% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $4.7M in revenue. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Entrada Therapeutics, Inc. has filed alongside them.

FY2025 annual
Revenue $25.4M
YoY -87.9%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

TRDA Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
Revenue$4.7M$25.4M-87.9%$210.8M+63.4%$129.0MN/AN/AN/A

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

TRDA Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Revenue$898K-53.9%$875K-95.7%$1.3M-96.5%$1.6M-91.8%$1.9M-97.9%$20.6M-65.2%$37.4M-10.6%$19.6M-55.3%$94.7M+421.2%$59.1M+134.0%$41.8M$43.7M

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Entrada Therapeutics, Inc. financials

Frequently Asked Questions

What was Entrada Therapeutics, Inc.'s revenue in fiscal year 2025?

Entrada Therapeutics, Inc. generated $25.4M in revenue in fiscal year 2025.

How fast is Entrada Therapeutics, Inc.'s revenue growing?

Entrada Therapeutics, Inc. (TRDA) revenue fell by 87.9% year over year, from $210.8M to $25.4M in fiscal year 2025.

What is Entrada Therapeutics, Inc.'s revenue over the last twelve months?

Entrada Therapeutics, Inc. (TRDA) reported $4.7M in revenue over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Entrada Therapeutics, Inc. (TRDA) reported $898K in revenue in Q2 2026. This represents a decrease of 53.9% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Entrada Therapeutics, Inc. (TRDA) reported on that line in every period on record.